Impact of Reversion of Mycobacterium tuberculosis Immunoreactivity Tests on the Estimated Annual Risk of Tuberculosis Infection.


Journal

American journal of epidemiology
ISSN: 1476-6256
Titre abrégé: Am J Epidemiol
Pays: United States
ID NLM: 7910653

Informations de publication

Date de publication:
10 11 2023
Historique:
received: 17 06 2022
revised: 26 12 2022
accepted: 02 02 2023
medline: 4 12 2023
pubmed: 8 2 2023
entrez: 7 2 2023
Statut: ppublish

Résumé

A key metric in tuberculosis epidemiology is the annual risk of infection (ARI), which is usually derived from tuberculin skin test (TST) and interferon-γ release assay (IGRA) prevalence surveys carried out in children. Derivation of the ARI assumes that immunoreactivity is persistent over time; however, reversion of immunoreactivity has long been documented. We used a deterministic, compartmental model of Mycobacterium tuberculosis (Mtb) infection to explore the impact of reversion on ARI estimation using age-specific reversion probabilities for the TST and IGRA. Using empirical data on TST reversion (22.2%/year for persons aged ≤19 years), the true ARI was 2-5 times higher than that estimated from immunoreactivity studies in children aged 8-12 years. Applying empirical reversion probabilities for the IGRA (9.9%/year for youths aged 12-18 years) showed a 1.5- to 2-fold underestimation. ARIs are increasingly underestimated in older populations, due to the cumulative impact of reversion on population reactivity over time. Declines in annual risk did not largely affect the results. Ignoring reversion leads to a stark underestimation of the true ARI in populations and our interpretation of Mtb transmission intensity. In future surveys, researchers should adjust for the reversion probability and its cumulative effect with increasing age to obtain a more accurate reflection of the burden and dynamics of Mtb infection.

Identifiants

pubmed: 36749011
pii: 7030272
doi: 10.1093/aje/kwad028
pmc: PMC10691197
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1937-1943

Commentaires et corrections

Type : CommentIn

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health.

Références

Nat Rev Immunol. 2018 Sep;18(9):575-589
pubmed: 29895826
PLoS Med. 2016 Oct 25;13(10):e1002152
pubmed: 27780211
Lancet Infect Dis. 2021 Mar;21(3):354-365
pubmed: 33508224
Lancet Infect Dis. 2018 Aug;18(8):834-835
pubmed: 30064672
Epidemiol Infect. 1997 Oct;119(2):183-201
pubmed: 9363017
Paediatr Respir Rev. 2004;5 Suppl A:S135-7
pubmed: 14980258
BMJ. 2019 Oct 24;367:l5770
pubmed: 31649096
Clin Chest Med. 2019 Dec;40(4):829-837
pubmed: 31731987
Clin Infect Dis. 2023 Feb 8;76(3):e965-e972
pubmed: 35666515
Lancet Microbe. 2021 Jun;2(6):e267-e275
pubmed: 34100007
Clin Infect Dis. 2002 Feb 1;34(3):365-70
pubmed: 11774084
Int J Tuberc Lung Dis. 1999 Nov;3(11):962-75
pubmed: 10587318
Eur Respir J. 2016 Jul;48(1):168-78
pubmed: 27230438
Int J Tuberc Lung Dis. 2010 Apr;14(4):406-12
pubmed: 20202297
Am J Respir Crit Care Med. 2017 Sep 1;196(5):638-648
pubmed: 28737960
Bull Int Union Tuberc. 1969 Aug;42:1-104
pubmed: 5004883
Clin Infect Dis. 2012 Mar;54(6):784-91
pubmed: 22267721
Am J Respir Crit Care Med. 2015 Mar 1;191(5):584-91
pubmed: 25562578
Clin Infect Dis. 2021 Sep 15;73(6):1037-1045
pubmed: 33772550
Bull World Health Organ. 2002;80(6):503-11; discussion 501-2
pubmed: 12132011
Am Rev Respir Dis. 1964 Nov;90:707-20
pubmed: 14211457
Int J Tuberc Lung Dis. 2013 Jun;17(6):738-44
pubmed: 23676155
PLoS One. 2022 Mar 18;17(3):e0265036
pubmed: 35302992
Nat Rev Dis Primers. 2016 Oct 27;2:16076
pubmed: 27784885
Lancet Infect Dis. 2022 Sep;22(9):e271-e278
pubmed: 35526558

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH